NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ResMed (RMD) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
ResMed (RMD) gains from promising financial results in the fourth quarter of fiscal 2019.
Here's Why You Should Hold Onto Insulet (PODD) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on Insulet's (PODD) solid prospects.
Boston Scientific Rides on New Products Amid Dull Pacer Sales
by Zacks Equity Research
Within MedSurg, Boston Scientific (BSX) is on track for the year-end launch of Exalt-D Single-Use Duodenoscope, which is used in ERCP procedures.
Baxter (BAX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Baxter (BAX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Canopy Growth Set to Acquire Beckley Canopy Therapeutics
by Zacks Equity Research
With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.
National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.
Haemonetics (HAE) Beats on Q1 Earnings, Raises '19 EPS View
by Zacks Equity Research
Haemonetics (HAE) Q1 performance by all business sections has been impressive, except for BloodCenter.
NUVA vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. RMD: Which Stock Is the Better Value Option?
Will NuVasive Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor NuVasive.
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
NuVasive (NUVA) witnesses balanced revenue growth across majority of key operating segments.
NuVasive (NUVA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 12.50% and 0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Buy 6 Top Stocks Set to Beat on Earnings in Q2 Today
by Nalak Das
Second-quarter 2019 earnings expectations have improved this month. In spite of a prolonged trade conflict with China, we do not see a broad-based decline in guidance by U.S. corporates.
Why the Earnings Surprise Streak Could Continue for NuVasive (NUVA)
by Zacks Equity Research
NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NuVasive (NUVA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein Closes Acquisition of Elite Computer Italia
by Zacks Equity Research
The Elite Computer acquisition marks Henry Schein's (HSIC) foray into the Italian dental practice management software market.
NextGen Inks Deal With Appriss Health, Boosts EHR System
by Zacks Equity Research
NextGen (NXGN) integrates Appriss Health prescription monitoring and tracking analytics into NextGen Office that is likely to enhance the former's EHR system.
Intuitive Surgical to Boost da Vinci Platform With Buyout
by Zacks Equity Research
Intuitive Surgical's (ISRG) acquisition of Scholly Fiberoptic's robotic endoscope business to likely boost the acquirer's da Vinci Surgical system.
Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak
by Zacks Equity Research
Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.
Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.
Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand
by Zacks Equity Research
The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.
ABT or BIO: Which Stock Has Better Potential Right Now?
by Zacks Equity Research
Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.
Here's Why You Should Hold Onto Neogen (NEOG) Stock Now
by Zacks Equity Research
Investors' trust continues to be high in Neogen (NEO), thanks to strength in its Food Safety and Genomic businesses.
TFX or STE: Which is a Better Investment Pick Right Now?
by Zacks Equity Research
STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.
NuVasive (NUVA) Launches Pulse Integrated Technology Platform
by Zacks Equity Research
The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.
NuVasive Grows on Strong Product Adoption Amid Pricing Woe
by Zacks Equity Research
Introduction of multiple products within the Spinal Hardware, balanced revenue growth across key operating segments and robust international sales perk up NuVasive's (NUVA) share price.